SAB Biotherapeutics (SABS) News Today

SAB Biotherapeutics, Inc. (NASDAQ: SABS) is getting a mixed but mostly supportive read from Wall Street, which may be helping the stock find some backing even as the company remains unprofitable.

• Positive Sentiment: HC Wainwright reiterated a Buy rating on SAB Biotherapeutics and kept a $10.00 price target, signaling meaningful upside potential versus the current share price. HC Wainwright Issues Positive Forecast for SAB Biotherapeutics (NASDAQ:SABS) Stock Price
• Neutral Sentiment: The firm also published detailed earnings estimates for 2026-2030, with losses expected to narrow over time, which suggests analysts see a gradual long-term improvement rather than an immediate turnaround.
• Neutral Sentiment: Zacks Research upgraded SAB Biotherapeutics from “strong sell” to “hold,” indicating sentiment has improved somewhat, but not yet enough to call the shares attractive. Tickerreport.com
• Negative Sentiment: The analyst updates still point to continued losses, including an expected full-year 2026 EPS of ($1.10), reinforcing concerns that SAB Biotherapeutics is not close to profitability yet.
• Negative Sentiment: The company recently reported quarterly EPS of ($0.35), missing Wall Street’s estimate, which may be weighing on investor confidence.

Overall, SAB Biotherapeutics (SABS) appears to be moving on a mix of improved analyst sentiment and a high price target, but the persistent loss profile and recent earnings miss remain key headwinds for the stock.